Salud financiera de hoja de balance de Adaptive Biotechnologies
Salud financiera controles de criterios 4/6
Adaptive Biotechnologies tiene un patrimonio de los accionistas total de $308.3M y una deuda total de $130.7M, lo que sitúa su ratio deuda-patrimonio en 42.4%. Sus activos y pasivos totales son $661.1M y $352.9M respectivamente.
Información clave
42.4%
Ratio deuda-patrimonio
US$130.66m
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$346.40m |
| Patrimonio | US$308.28m |
| Total pasivo | US$352.86m |
| Activos totales | US$661.13m |
Actualizaciones recientes sobre salud financiera
Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Oct 13
Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Jul 06We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely
Apr 15Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans
Dec 13We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate
Aug 14Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth
Apr 29Recent updates
It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks
Apr 03Adaptive Biotechnologies: A Post Earnings Assessment
Feb 25Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically
Feb 17Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%
Feb 01Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be
Nov 17Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Oct 13Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Jul 06Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding
May 05We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely
Apr 15Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans
Dec 13Adaptive Biotechnologies, Epic team up to integrate clonoSEQ test in electronic record system
Oct 11Adaptive Biotechnologies announces $250M non-dilutive royalty financing
Sep 12We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate
Aug 14Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth
Apr 29Adaptive Biotechnologies: Good Buy For Long-Term Investors
Apr 15Are Investors Undervaluing Adaptive Biotechnologies Corporation (NASDAQ:ADPT) By 22%?
Feb 26We Think Adaptive Biotechnologies (NASDAQ:ADPT) Can Afford To Drive Business Growth
Jan 09Our First Assessment On Adaptive Biotechnologies
Dec 16Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans
Sep 26Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($410.2M) de ADPT superan a sus pasivos a corto plazo ($88.0M).
Pasivo a largo plazo: Los activos a corto plazo de ADPT ($410.2M) superan a sus pasivos a largo plazo ($264.8M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: ADPT tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de ADPT ha crecido de 0% a 42.4% en los últimos 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: ADPT tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: Datos insuficientes para determinar si ADPT tiene suficiente cash runway en caso de que su flujo de caja libre siga creciendo o disminuyendo basado en tasas históricas.